GILD - Gilead Sciences - Stock Forecast

Healthcare - Sector
Coverage Profile Performance Price Targets & Ratings Chart Insider Trading

GILD is currently covered by 23 analysts with an average price target of $90.69. This is a potential upside of $17.99 (24.75%) from yesterday's end of day stock price of $72.7.

Gilead Sciences's activity chart (see below) currently has 498 price targets and 456 ratings on display. The stock rating distribution of GILD is 61.86% HOLD, 35.05% BUY and 3.09% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 57.77% with an average time for these price targets to be met of 692.25 days.

Highest price target for GILD is $105, Lowest price target is $75, average price target is $90.69.

Most recent stock forecast was given by ROBYN KARNAUSKAS from TRUIST on 22-Feb-2024. First documented stock forecast 18-Mar-2013.

Split History since 2000:

1/28/13 2 for 1

6/25/07 2 for 1

9/7/04 2 for 1

3/8/02 2 for 1

2/22/01 2 for 1

What is Gilead Sciences?

Gilead Sciences is a bio pharmaceutical company that specializes in discovering, developing, and commercializing innovative medicines for the treatment of unmet medical needs. Founded in 1987 and headquartered in Foster City, California, the company operates in the United States, Europe, and other parts of the world.

What made Gilead Sciences famous?

Gilead Sciences is known for its groundbreaking research and development of antiviral drugs for the treatment of HIV/AIDS. The company’s products have transformed the treatment of HIV/AIDS, allowing patients to live longer and healthier lives. Gilead Sciences has also gained recognition for its innovative therapies in oncology, hematology, and cell therapy.

What are the famous products or services of Gilead Sciences?

Gilead Sciences focuses on addressing unmet medical needs in several therapeutic areas with a diverse portfolio of products. Here are some of the key product segments:


Gilead Sciences is a leader in developing therapies for HIV/AIDS, and the company’s HIV franchise includes several products such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. These products help to suppress the virus and slow down the progression of the disease, improving the quality of life for patients living with HIV/AIDS.

Viral hepatitis

Gilead Sciences’ products for viral hepatitis include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Doctors use these products to treat chronic viral infections caused by hepatitis B and C, which can lead to serious health problems such as liver damage and cancer.


Gilead Sciences’ oncology franchise includes Yescarta, Tecartus, Trodelvy, and Zydelig. Various types of cancers, including lymphoma, leukemia, and breast cancer, are treated with these products. The company is also investing in research and development to develop new oncology therapies.

Pulmonary arterial hypertension

Gilead Sciences developed Letairis, an oral formulation used to treat pulmonary arterial hypertension, a type of high blood pressure that affects the arteries in the lungs.

Invasive fungal infections

Gilead Sciences developed AmBisome, a liposomal formulation that treats serious invasive fungal infections like aspergillosis and cryptococcosis.

They are also investing in cell therapy and gene editing technologies to develop new therapies for a wide range of diseases, including cancer, HIV/AIDS, and genetic disorders.

Currently out of the existing stock ratings of GILD, 60 are a HOLD (61.86%), 34 are a BUY (35.05%), 3 are a SELL (3.09%).

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$8.98 (12.30%)


6 days ago

21/35 (60%)

$9.22 (12.67%)




$16.98 (23.25%)


6 days ago

8/13 (61.54%)

$17.22 (23.66%)




$1.98 (2.71%)


14 days ago

27/62 (43.55%)

$1.96 (2.68%)




$6.98 (9.56%)


16 days ago

11/14 (78.57%)

$5.55 (7.45%)




$31.98 (43.80%)


16 days ago

4/11 (36.36%)

$30.55 (41.03%)


Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GILD (Gilead Sciences) average time for price targets to be met?

On average it took 692.25 days on average for the stock forecasts to be realized with a an average price target met ratio 57.77

Which analyst has the current highest performing score on GILD (Gilead Sciences) with a proven track record?


Which analyst has the most public recommendations on GILD (Gilead Sciences)?

Katherine Breedis has 2 price targets and 4 ratings on GILD

Which analyst is the currently most bullish on GILD (Gilead Sciences)?

Do Kim with highest potential upside - $38.98

Which analyst is the currently most reserved on GILD (Gilead Sciences)?

Andrew Berens with lowest potential downside - -$5.02

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?